The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Imetelstat shows activity in patients with myeloproliferative neoplasms, including primary myelofibrosis (PMF) and essential thrombocythemia. Here, we describe a case of prolonged disease stabilization by imetelstat treatment of a high-risk PMF patient enrolled into the clinical study MYF2001. We co...

Full description

Bibliographic Details
Main Authors: Kathrin Olschok, Bianca Altenburg, Marcelo A. S. de Toledo, Angela Maurer, Anne Abels, Fabian Beier, Deniz Gezer, Susanne Isfort, Katrin Paeschke, Tim H. Brümmendorf, Martin Zenke, Nicolas Chatain, Steffen Koschmieder
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
Myeloproliferative neoplasms (MPN)
imetelstat (GRN163L)
myelofibrosis (MF)
induced pluripotent stem cells
telomere length (TL)
JAK2V617F
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1277453/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1277453/full

Similar Items